Section 3 of 6
Product information and disease description
277 evidence topics · 192 sources
Product description
Phase of product development
Australia: TGA provisional approval pathway eligibility and submission
Australia: duration of provisional registration
Company-projected approval and launch timing
Regulatory status: Under review; TGA provisional approval application submitted March 2026
Launch: Anticipated as early as 2027, market not specified
United States, Canada, and United Kingdom: clinical trial authorizations
FDA or EMA marketing application, orphan, fast track, breakthrough therapy, or PRIME designations
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Skyhawk Therapeutics
Nonproprietary name and brand name
No evidence found.
Dosage forms and strengths
Oral tablet: open-label extension study
Strengths studied: healthy volunteers
Strengths studied: participants with HD
Strengths studied: phase 2/3 FALCON-HD
Commercial formulation and strength
No evidence found.
Average sales price and wholesale acquisition cost
Product price and anticipated annual cost per participant
Not applicable.
American hospital formulary service (AHFS), or other drug classification
AHFS classification
No evidence found.
Indication
Pharmacology
Mechanism of action
HTT lowering through splicing modulation
Molecular mechanism: cryptic exon inclusion in HTT pre-mRNA
Target selectivity: independent commentary
Pharmacodynamics
Preclinical pharmacology: human cells and Hu97/18 mice
Participants with HD: blood mRNA and mHTT protein at day 84
Participants with HD: blood mHTT and total HTT protein through 12 months
Participants with HD: biomarker reductions through 15 months
Neurofilament light chain
CSF markers of neuroinflammation and neuronal injury
Caudate volume and volumetric MRI results
No evidence found.
Pharmacokinetics
Participants with HD: dose proportionality and steady state
Terminal half-life, food effect results, metabolism, and renal excretion
No evidence found.
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, contraindications, boxed warnings, and REMS
Not applicable.
Most common adverse events observed in clinical studies
Special populations
Age range studied
| Study | Quoted criterion |
|---|---|
| Part C, participants with HD | “Males and females, aged between 25 and 70 years.” |
Renal and hepatic impairment: phase 1 exclusion criteria
Pregnancy, lactation, and contraception: phase 2/3 criteria
Psychiatric history: phase 2/3 exclusion
Pediatric and juvenile-onset HD, pharmacokinetics in renal or hepatic impairment
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on SKY-0515
Protocol restriction: St. John’s Wort
Clinical drug interaction studies
No evidence found.
Effects of SKY-0515 on other drugs
Clinical drug interaction studies
No evidence found.
Dosing and administration
Dosage
Proposed commercial dose and dose adjustment
No evidence found.
Administration
Administration with food
No evidence found.
Access and distribution
Current access through clinical trials only
Expanded access program, specialty distribution, and REMS
No evidence found.
Co-prescribed/Concomitant therapies
Part C: permitted background HD medications
Part C: changes in background therapy as intercurrent events
FALCON-HD: prior gene therapy exclusion
Baseline concomitant medication use in studied participants
No evidence found.
Effect of SKY-0515 on quality measures
AAN movement disorders quality measurement sets: conditions covered
SKY-0515-specific effect on quality measures
No evidence found.
Product comparison
Summary
No head-to-head clinical comparison of SKY-0515 with an approved symptomatic therapy or with another huntingtin-lowering agent has been reported. The investigational disease-modifying candidates differ in route: SKY-0515 and votoplam are oral small-molecule splicing modifiers, tominersen is an intrathecal antisense oligonucleotide, and AMT-130 is a one-time gene therapy delivered by stereotactic neurosurgery into the striatum. Efficacy claims for AMT-130, votoplam, and SKY-0515 beyond 12 months rest on comparisons with propensity-weighted, propensity score-matched, or overlap-weighted natural history cohorts rather than concurrent randomized controls. Sponsor announcements describe SKY-0515 mHTT lowering as the greatest demonstrated in patients; independent commentary noted that the SKY-0515 and votoplam studies differ too much in length, size, and data presentation for a true comparison. In the placebo-controlled phase 3 GENERATION HD1 trial of intrathecal tominersen (791 participants), treatment was stopped in March 2021; in an ad hoc week 69 analysis, the cUHDRS change with 120 mg every 8 weeks was significantly worse than with placebo (-0.54 points; adjusted P=0.001), neither cUHDRS nor TFC change with the every-16-week regimen differed significantly from placebo, and more adverse events occurred with the every-8-week regimen. Among approved symptomatic agents, no blinded head-to-head RCT of VMAT2 inhibitors exists; two indirect comparisons of the TETRA-HD and First-HD trials reached different overall conclusions on safety, and an open-label randomized trial of 179 participants compared tetrabenazine, tiapride, and olanzapine.
SKY-0515 in relation to huntingtin-only lowering: independent trials review
“SKY-0515 is designed to reduce both HTT and PMS1 proteins, the latter implicated in somatic CAG repeat expansion, a mechanistic process increasingly recognised as a key driver of neuronal loss in HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This important phase II/III clinical trial of SKY-0515 will assess whether HTT and PMS1 lowering can offer greater therapeutic benefit than HTT reduction alone in early-stage HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Magnitude of HTT lowering relative to other agents: statements in sponsor announcements
HTT lowering targets in other trials: independent commentary
Route of administration compared with antisense oligonucleotides and gene therapy
Investigational disease-modifying candidates: differences in route and regimen
“Furthermore, the DMTs currently under development vary in mechanism of action (small molecule, ASO, gene therapy), route of administration (oral, intrathecal, intraparenchymal), and once vs recurrent therapy; these contingencies make it difficult at this time to assign a DMT price in our exploratory analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
cUHDRS component pattern compared with votoplam
External natural-history comparisons across HTT-lowering trials
AMT-130 (ifezuntirgene inilparvovec): administration and regulatory submissions
AMT-130: 36-month topline results versus external controls
“The prespecified analysis included 29 treated participants (17 high-dose, 12 low-dose), with 12 patients per cohort reaching 36 months of follow-up. Outcomes were compared with propensity score-matched external controls from the Enroll-HD natural history dataset (n = 940 for high dose; n = 626 for low dose). At 36 months, high-dose AMT-130 met the primary endpoint, demonstrating a statistically significant 75% slowing of disease progression versus controls, as measured by the cUHDRS” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AMT-130: FDA position after the January 2026 Type A meeting
AMT-130: FDA position after the June 2026 Type B meeting
Tominersen: phase 3 GENERATION HD1 dosing discontinued
Tominersen: GENERATION HD1 design and primary end points
“in which 791 participants with manifest Huntington’s disease were randomly assigned in a 1:1:1 ratio to receive intrathecal tominersen, at a dose of 120 mg every 8 weeks or every 16 weeks, or placebo” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was the change from baseline in the score on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) or Total Functional Capacity (TFC) scale at week 101.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Biomarker end points included levels of mutant HTT in CSF, levels of neurofilament light protein (NfL) in CSF, and ventricular volume.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: GENERATION HD1 ad hoc week 69 clinical results
“On the basis of an overall benefit–risk assessment by an independent data monitoring committee, treatment was stopped in March 2021; therefore, an ad hoc analysis of the results at week 69 was carried out” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the every-8-week tominersen group, the mean change from baseline in the score on the cUHDRS at week 69 was significantly worse than that in the placebo group (−0.54 points, adjusted P=0.001), but the mean change from baseline in the score on the TFC scale did not differ significantly (−0.40 points, adjusted P=0.09).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the every-16-week tominersen group, the mean changes from baseline in the scores on the cUHDRS and the TFC scale did not differ significantly from those in the placebo group (−0.16 points, adjusted P=0.84; and −0.04, adjusted P=1.00, respectively)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nonetheless, these results must be interpreted with caution, given the ad hoc nature of the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: GENERATION HD1 biomarkers, adverse events, and post hoc subgroup analyses
“The changes in mutant HTT levels in CSF were consistent with dose regimen–dependent decreases and concomitant increases in ventricular volume” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The absence of whole-brain volume loss in the context of ventricular expansion and the absence of a correlation between the change in CSF NfL levels and change in ventricular volume suggest that increases in ventricular volume do not reflect increased atrophy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A transient increase was seen in CSF NfL levels in the every-8-week tominersen group at week 21; although neuroaxonal damage may be implicated, increased levels of leukocytes and total protein in CSF in some participants suggest an inflammatory component” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More adverse events occurred in the participants in the every-8-week tominersen group than in those in the placebo group and the every-16-week tominersen group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The results of post hoc analyses support the hypothesis that younger participants (who have less disease burden) may benefit from tominersen therapy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“this hypothesis is currently being tested in a phase 2 dose-finding trial (GENERATION HD2; NCT05686551).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: phase 2 GENERATION HD2
“GENERATION HD2 is a phase II, randomised, double-blind, placebo-controlled, dose-finding clinical trial comparing 60 mg tominersen, 100 mg tominersen and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical trial remains ongoing, and definitive conclusions regarding clinical benefit will only be possible once the data are unblinded and fully analysed. This is anticipated to be late 2026.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Votoplam: oral splicing modifier, 24-month extension versus natural history
Votoplam: route and 12-week PIVOT-HD primary endpoint
“PTC518 (also known as votoplam), an orally administered huntingtin mRNA splice modulator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study met its primary endpoint, showing dose-dependent reductions in blood HTT protein levels at week 12, along with a favourable safety and tolerability profile across all dose levels and disease stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pridopidine: phase 3 PROOF-HD and EMA opinion
“The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington's Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled comparison of investigational agents with standard of care: tominersen and AMT-130
“Compared with SoC, Tominersen increased costs by $2.11 million and QALYs by 0.93, resulting in an ICER of $2.28 million per QALY gained, whereas AMT-130 increased costs by $1.49 million and QALYs by 5.23, resulting in an ICER of $285,703 per QALY gained in the base case.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Approved VMAT2 inhibitors: indirect tolerability comparison of deutetrabenazine and tetrabenazine
“Compared with tetrabenazine, deutetrabenazine was associated with a significantly lower risk of moderate to severe AEs and neuropsychiatric AEs including agitation, akathisia, depression, depression/agitated depression, drowsiness/somnolence, insomnia, and parkinsonism in both adjusted and unadjusted analyses (p < 0.05 for each).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approved VMAT2 inhibitors: GRADE-based indirect comparison
Symptomatic antichoreic agents: open-label randomized comparison of tetrabenazine, tiapride, and olanzapine
“We conducted a pragmatic, randomized, open-label trial across 11 centers of the French-Speaking Huntington's Network, enrolling 179 patients with Huntington's disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tetrabenazine was most frequently associated with mood disorders and sedation, while olanzapine caused occasional weight gain and mild increases in LDL and total cholesterol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direct head-to-head clinical comparison with votoplam, AMT-130, tominersen, WVE-003, or another active therapy
No evidence found.
Place of product in therapy
Disease description
Definition and etiology
Definition: progressive motor, cognitive, and psychiatric disorder
Etiology: expanded CAG repeat in HTT encoding a polyglutamine tract
“The disease is caused by an expanded CAG trinucleotide repeat (of variable length) in HTT, the gene that encodes the protein huntingtin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Huntington's disease is an autosomal-dominant, progressive neurodegenerative disorder with a distinct phenotype, including chorea and dystonia, incoordination, cognitive decline, and behavioural difficulties.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CAG repeat length thresholds
| Allele category | CAG repeat length |
|---|---|
| Normal alleles | “26 or fewer CAG repeats” |
| Intermediate alleles | “27 to 35 CAG repeats” |
| Reduced-penetrance HD-causing alleles | “36 to 39 CAG repeats” |
| Full-penetrance HD-causing alleles | “40 or more CAG repeats” |
Reduced penetrance of 36 to 39 CAG repeat alleles
“Variable penetrance for alleles carrying 36-39 repeats has been noted, but the disease appears fully penetrant when the repeat numbers are >40.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 18 of 7,315 individuals had ≥36 CAG, revealing that approximately 1 in 400 individuals from the general population have an expanded CAG repeat associated with HD (0.246%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The infrequent diagnosis of HD at this CAG length is likely due to low penetrance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CAG repeat length and age of onset
Juvenile Huntington's disease and anticipation
Epidemiology
Incidence of Huntington's disease
Global incidence: updated systematic review and meta-analysis, 2010 to 2022
“A total of 33 studies published between 2010 and 2022 were included. Pooled incidence was 0.48 cases per 100,000 person-years (95% CI, 0.33-0.63). Subgroup analysis by continent demonstrated a significantly higher incidence of HD in Europe and North America than in Asia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global incidence: systematic review and meta-analysis, 1985 to 2010
“Meta-analysis of data from four incidence studies revealed an incidence of 0.38 per 100,000 per year (95% confidence interval [CI]: 0.16, 0.94). Lower incidence was reported in the Asian studies (n = 2), compared to the studies performed in Europe, North America, and Australia (n = 6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States incidence: commercial insurance claims, 2003 to 2016
“Using an insurance database of over 67 million enrollees, we retrospectively identified a cohort of 3,707 individuals diagnosed with Huntington’s disease between 2003–2016.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated a cumulative age-adjusted HD frequency rate of 6.52 per 100,000 persons and a cumulative incidence rate of 1.22 per 100,000 person years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States incidence: Medicare beneficiaries aged 65 years or older
“In the Medicare population, 1,941 prevalent and 819 incident cases of HD were identified in 2017, corresponding to a prevalence proportion of 13.1 per 100,000 persons and incidence rate of 6.1 per 100,000 person-years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom incidence: primary care records
“The data showed that the incidence of HD has remained constant between 1990 and 2010 with an overall rate of 7.2 (95% CI 6.5 to 7.9) per million person-years. The systematic review identified 14 independent estimates of incidence with substantial heterogeneity and consistently lower rates reported in studies from East Asia compared with those from Australia, North America and some--though not all--those from Europe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 586 incident cases of HD from a total at‐risk population of 10,756,901 persons (corresponding to 80,048,926 PY) during the study period (Table 1). There was no evidence that incidence increased over time (β = 0.004, p = 0.4), with 16–44 newly diagnosed cases per year identified. In 2018, incidence of HD was 0.8 (0.5–1.19) per 100,000 PY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Huntington's disease
Global prevalence: updated systematic review and meta-analysis
Global prevalence: systematic review and meta-analysis, by region
“The worldwide service-based prevalence of HD, based on a meta-analysis (n = 13 studies), was 2.71 per 100,000 (95% CI: 1.55-4.72). Eleven studies were conducted in Europe, North American, and Australia, with an overall prevalence of 5.70 per 100,000 (95% CI: 4.42-7.35). Three studies were conducted in Asia, with an overall prevalence of 0.40 per 100,000 (95% CI: 0.26-0.61).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Geographic variation and prevalence trends
“The prevalence of HD varies more than tenfold between different geographical regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of an increasing prevalence of between 15 and 20% per decade in studies from Australia, North America and Western Europe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: symptomatic and at-risk population
United States: claims-based prevalence
“In the Medicare population, 1,941 prevalent and 819 incident cases of HD were identified in 2017, corresponding to a prevalence proportion of 13.1 per 100,000 persons and incidence rate of 6.1 per 100,000 person-years. In the Medicaid population, 353 prevalent cases of HD were identified in 2014, corresponding to a prevalence proportion of 15.2 per 100,000 persons.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom: primary care prevalence
“The estimated prevalence (expressed per 100 000 population) rose from 5.4 (95% CI 3.8 to 7.5) in 1990 to 12.3 (95% CI 11.2 to 13.5) in 2010.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual prevalence steadily increased throughout the study period, with prevalence estimates ranging from 4.3 cases (3.6–5.1) per 100,000 in 2000 to 9.2 cases (8.1–10.5) per 100,000 people in 2018 (β = 0.27, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Juvenile and pediatric Huntington's disease: proportion in Enroll-HD
Natural history, survival, and mortality
Age at onset and prodromal phase
Prodromal change detected before diagnosis: PREDICT-HD
“1078 individuals with a CAG expansion were included in this analysis. Participants were followed up for a mean of 5·1 years (SD 3·3, range 0·0-12·0). 225 (21%) of these participants received a motor diagnosis of Huntington's disease during the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disease stages: Huntington's Disease Integrated Staging System
“The HD-ISS characterises individuals for research purposes from birth, starting at Stage 0 (ie, individuals with the Huntington's disease genetic mutation without any detectable pathological change) by using a genetic definition of Huntington's disease. Huntington's disease progression is then marked by measurable indicators of underlying pathophysiology (Stage 1), a detectable clinical phenotype (Stage 2), and then decline in function (Stage 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression in premanifest and early disease: TRACK-HD
Survival after onset and age at death
“For these fully ascertained subjects, the range, mean, SD, and median of duration values were 0–46, 15.4, 6.8, and 15 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found that, as with clinical onset, HD age at death is determined by expanded CAG-repeat length and has no contribution from the normal CAG allele. Surprisingly, disease duration is independent of the mutation's length.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality relative to the general population: UK cohort
“The KM survival curve (Figure 1) shows a median survival time of 12.4 years (95% CI 10.6–15.2). Median age at death in individuals with HD and controls was 71 (IQR 59–79) and 81 (IQR 73–86) years, respectively. Individuals with HD were at 4.5 times greater risk of death than controls (hazard ratio 4.51, 95% CI 3.36–6.06, p < 0.001) after multivariable adjustment of baseline covariates (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at death and causes of death: Norwegian national registries
“Mean age at death for individuals with HD was found to be 63.9 years (NCDR) and 61.7 years (CRD), compared to a mean of 76.9 years in the general population (NCDR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 73.5% of individuals with HD, the underlying cause of death was HD, followed by cardiovascular diseases, cancer and respiratory diseases. The most common immediate cause of death was respiratory diseases (44.2%). Suicide was a more common cause of death in the population with HD (2.3%) compared to the general population (1.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Causes of death: aspiration pneumonia
“Two hundred twenty four charts of deceased HD patients were reviewed, of which 216 (111/104 male/female, one unknown) had records available, 147 listed a cause of death (Table 1), which was pneumonia in 81 (55%) cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The conclusion is that the majority (86.8%) of our HD patients where the cause of death could be identified died from aspiration pneumonia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicide and suicidal ideation
“Incidence of suicidal ideation, suicide attempt, and suicide are higher among those with HD relative to the non-HD population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, 169 (8.0%) mutation carriers endorsed suicidal ideation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 4-year cumulative incidence of suicidal ideation was 9.9%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Juvenile Huntington's disease: progression and survival
“Disease progression of JHD is faster compared to AOHD and the disease duration is shorter, particularly in case of higher CAG repeat lengths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease progression was more rapid in juvenile Huntington's disease (n=14) than in adult-onset Huntington's disease (n=52; generalised estimating equation model, p=0·0003). Of 121 deceased patients, median survival was shorter in the juvenile Huntington's disease (n=17) cohort than in adult-onset Huntington's disease (n=104) cohort (hazard ratio 2·18 [95% CI 1·08-4·40]; p=0·002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Mutant huntingtin: toxic gain of function
“In mutation carriers, huntingtin is produced with abnormally long polyglutamine sequences that confer toxic gains of function and predispose the protein to fragmentation, resulting in neuronal dysfunction and death.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the cellular level mutant huntingtin results in neuronal dysfunction and death through a number of mechanisms, including disruption of proteostasis, transcription and mitochondrial function and direct toxicity of the mutant protein. Early macroscopic changes are seen in the striatum with involvement of the cortex as the disease progresses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Striatal degeneration: neuropathological grading
“The earliest changes were seen in the medial paraventricular portions of the caudate nucleus (CN), in the tail of the CN, and in the dorsal part of the putamen. Counts of neurons in the CN reveal that 50% are lost in grade 1 and that 95% are lost in grade 4” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genetic modifiers of onset: DNA repair genes identified by GWAS
“Association at MLH1 and pathway analysis of the full GWA results support a role for DNA handling and repair mechanisms in altering the course of HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The timing of onset shows no significant association with HTT cis-eQTLs but is influenced, sometimes in a sex-specific manner, by polymorphic variation at multiple DNA maintenance genes, suggesting that the special onset-determining property of the uninterrupted CAG repeat is a propensity for length instability that leads to its somatic expansion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four genes at 3 loci were significant after Bonferroni correction: FAN1 (p = 1.9E-22), MSH3 (1.9E-8), PMS1 (6.1E-7), and ASNSD1 (5.3E-6) with later onset associated with increased FAN1, PMS1, and ASNSD1 expression and decreased MSH3 expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic modifiers of progression: MSH3 and PMS1
“The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“encodes an aminoacid change (Pro67Ala) in MSH3” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Genome-wide association studies (GWASs) of Huntington disease (HD) have identified six DNA maintenance gene loci (among others) as modifiers and implicated a two step-mechanism of pathogenesis: somatic instability of the causative HTT CAG repeat with subsequent triggering of neuronal damage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, we identified additional modifier effects at the PMS1 and PMS2 loci and implicated a potential second locus on chromosome 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Somatic CAG repeat expansion in striatal projection neurons
“We found that the HTT CAG repeat expands somatically from 40-45 to 100-500+ CAGs in SPNs. Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect, but SPNs with 150-500+ CAGs lost positive and then negative features of neuronal identity, de-repressed senescence/apoptosis genes, and were lost.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that in HD, at any one time, most neurons have an innocuous but unstable HTT gene, and that HD pathogenesis is a DNA process for almost all of a neuron’s life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PMS1 as a modifier of somatic CAG repeat expansion
Multiple pathogenic mechanisms
“Mutant HTT (mHTT) disrupts transcription, interferes with immune and mitochondrial function, and is aberrantly modified post-translationally. Evidence suggests that the mHTT RNA is toxic, and at the DNA level, somatic CAG repeat expansion in vulnerable cells influences the disease course.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Establishing the diagnosis: clinical findings and molecular genetic testing
“The diagnosis is usually confirmed through identification of an increased CAG repeat length in the huntingtin gene in a patient with clinical features of the condition. Though diagnosis is usually straightforward, unusual presentations can occur, and it can be difficult to know when someone has transitioned from being an asymptomatic carrier into the disease state.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical motor diagnosis: diagnostic confidence level
“Huntington's disease (HD) is currently diagnosed based on the presence of motor signs indicating 99% "diagnostic confidence" for HD. Recent advances in the understanding of HD natural history and neurobiology indicate that disease-related brain changes begin at least 12 to 15 years before the formal diagnosis based on motor onset.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“with the gene mutation for Huntington's disease but without a motor diagnosis (a rating below 4 on the diagnostic confidence level from the 15-item motor assessment of the Unified Huntington's Disease Rating Scale)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Staging: Huntington's Disease Integrated Staging System
“The Huntington's Disease Integrated Staging System (HD-ISS) comprises a biological research definition and evidence-based staging centred on biological, clinical, and functional assessments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If there are signs of neurodegeneration, evidenced by atrophy of the caudate or putamen, individuals are assigned to stage 1. If disease signs are measurable by the TMS or Symbol Digit Modalities Test (SDMT), they are classified as stage 2. Finally, if there is an impact on daily functioning as assessed by the Total Functional Capacity (TFC) or the Independence Scale, individuals are assigned to stage 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical motor diagnosis, or a Diagnostic Confidence Level (DCL) of 4, corresponds to the latter part of HD-ISS stage 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Predictive genetic testing in at-risk individuals
Biomarkers: plasma neurofilament light protein
“Mean concentrations of NfL in plasma at baseline were significantly higher in HTT mutation carriers than in controls (3·63 [SD 0·54] log pg/mL vs 2·68 [0·52] log pg/mL, p<0·0001) and the difference increased from one disease stage to the next.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 104 individuals with premanifest Huntington's disease, NfL concentration in plasma at baseline was associated with subsequent clinical onset during the 3-year follow-up period (hazard ratio 3·29 per log pg/mL, 95% CI 1·48-7·34, p=0·0036).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Motor symptoms: dystonia, bradykinesia, rigidity, and oculomotor disturbance
Motor symptoms: gait disturbance and falls
Cognitive symptoms: executive dysfunction and progressive decline
“Chorea and other aspects of the movement disorder are the most visible aspect of the disease. However, non-motor features have greatest affect on functional independence and quality of life, so require recognition and management.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric symptoms: depression, irritability, apathy, and anxiety
“Ninety eight per cent of the patients exhibited neuropsychiatric symptoms, the most prevalent being dysphoria, agitation, irritability, apathy, and anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other symptoms: weight loss
Other symptoms: sleep and circadian disturbance
Juvenile Huntington's disease: presentation
Long-term morbidity
Loss of functional independence
Neuropsychiatric symptoms and functional capacity: systematic review
Falls and injury
“Twenty-seven patients (60%) reported two or more falls in the previous year and were classified as fallers. During prospective follow-up 40% reported at least one fall. A high proportion of falls (72.5%) caused minor injuries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three months before death, anxiety (11% vs. 5%, 2.11, 0.7–5.6, p = 0.15), depression (28% vs. 6%, 4.28, 1.72–8.67, p < 0.001), falls (25% vs. 8%, 2.5, 1.18–4.73, p < 0.05), insomnia (25% vs. 4%, 8.82, 3.62–20.19, p < 0.001) and fractures/breaks/sprains (20% vs. 10%, 1.83, 0.85–3.35, p = 0.09) were more prevalent in HD cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pneumonia, weight loss, dementia, and other comorbidities after diagnosis
“Incidence rates of the following were statistically higher in individuals with HD than controls: psychotic disorders, psychosis, insomnia, dementia, depression, pneumonia, weight loss and falls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most commonly mentioned causes of death (any mention) were HD (78.3%), bronchopneumonia (unspecified) (15.9%), pneumonitis due to food and vomiting (10.4%), unspecified dementia (6.6%) and sepsis (6.6%) (Table S8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Institutionalization: skilled nursing facility placement
“Among 4,809 subjects enrolled, 3,070 had clinically definite HD. Of these, 228 (7.4%) resided in SNF. The SNF residents' average age was 52 years, average disease duration was 8.6 years, and they were predominantly women (63%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the Cox model, bradykinesia (HR 1.965, 95% CI 1.083 to 3.564), impaired gait (HR 3.004, 95% CI 1.353 to 6.668), and impaired tandem walking (HR 2.546, 95% CI 1.460 to 4.439) were predictive of SNF placement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Juvenile Huntington's disease: long-term motor morbidity and seizures
“Compared with the LE subgroup, development delay (0 [0%] in the LE subgroup vs nine [90%] in the HE subgroup; p<0·0001), severe gait impairment (nine [35%] in the LE subgroup vs nine [90%] in the HE subgroup; p=0·0072), and seizures (three [11%] in the LE subgroup vs eight [80%] in the HE subgroup; p<0·0001) prevailed over time in the HE subgroup.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Huntington's disease
Humanistic burden and health-related quality of life
HDBOI study: EQ-5D-5L, SF-6D, and H-QoL-I scores by disease stage
“A total of 2,094 PwHD were enrolled with completed eCRFs (100%) and PPIE-P forms (n = 482, 23%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean EQ-5D-5L (n = 336) utility score was 0.59 (SD, 0.27), with the highest mean utility scores [SD] in ES (0.72 [0.22]) followed by MS (0.62 [0.18]) and AS (0.37 [0.30]), p < 0.001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean SF-6D score (n = 482) was 0.57 (SD, 0.10), with mean values decreasing with advanced disease (ES, 0.61; MS, 0.56; AS, 0.50, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“H-QoL-I mean scores (n = 482) also worsened with more advanced disease, from 0.58 for ES to 0.49 for MS and 0.37 for AS, p < 0.001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall proxy respondents reported on average worse outcomes than PwHD (self-reported) across all outcomes and disease stages suggesting a possible unawareness of deficits by PwHD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health state utility values: systematic literature review
“Of 383 articles screened, 16 articles reported utility values estimated in 11 distinct studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EQ-5D index range was 0.89 - 0.72 for mild/prodromal HD and 0.71 - 0.37 for severe/late-stage disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study uncovered high variability in published utility estimates, indicating substantial uncertainty in existing data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health state utility values: EHDN REGISTRY SF-6D analysis
“11,328 questionnaires were completed by 5560 respondents with HD in 12 European countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Women generally had lower HSUVs than men, and HSUVs were consistently lower than population norms for those with HD in the UK, and dropped with increasing disease severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with TFC score, Behavioural score, and male gender significant predictors of SF-6D values (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stage-specific utility values applied in a U.S. cost-effectiveness model
“Health utilities for SoC were derived from the Hawton et al. study” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“that used SF-6D preference-based measures to estimate stage-specific utilities for HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Norway cross-sectional study: EQ-5D-3L values by disease phase
“Mean HRQoL values declined across disease phases for the 84 participants; early phase (n = 34): mean = 0.84 (SD = 0.13), middle phase (n = 19): mean = 0.74 (SD = 0.10) and advanced phase (n = 31): mean = 0.65 (SD = 0.5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Spain: H-QoL-I and EQ-5D-3L
“Fifty-five patients and an equal number of caregivers participated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The usual activities and anxiety/depression were the most severely altered dimensions according to the EQ-5D-3L results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increase of disease severity resulted in lower patient QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chorea health states: time trade-off utility values in the general population
“Mean ± SD TTO-derived utility values were 0.07 ± 0.52, 0.26 ± 0.50, 0.48 ± 0.47, and 0.64 ± 0.41 for severe, moderate/severe, moderate/mild, and mild chorea severity, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents were willing to give up 3.6, 5.2, 7.4, and 9.3 years during a 10-year life span to avoid living with mild, mild/moderate, moderate/severe, and severe chorea, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HDQLIFE: development of a disease-specific HRQoL measurement system
“Existing item banks and new item pools were field tested in 536 individuals with prodromal, early-, or late-stage HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HDQLIFE encompasses both validated Neuro-QoL/PROMIS measures, as well as five new scales in order to provide a comprehensive assessment of HRQOL in HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HDQLIFE physical function measures: reliability and validity
“A total of 510 individuals with Huntington's disease completed 2 Quality of Life in Neurological Disorders (Lower Extremity Function and Upper Extremity Function) and 3 Huntington's Disease Health-Related Quality of Life (Chorea, Speech Difficulties, and Swallowing Difficulties) measures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reliabilities for the new patient reported physical functioning measures were excellent (all Cronbach's α > .92).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chorea and HRQoL: U.S. online survey using HDQLIFE
“A total of 115 participants (n = 35 caregivers; n = 80 individuals with HD) were included in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among those experiencing chorea (n = 83, 74% of respondents), 66% indicated it was 'Very Important' to manage chorea; however, only 47% agreed that their current medication regimen helped manage their movements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“significantly higher Anxiety (P = 0.0423) and stigma (P < 0.0001) scores were observed among respondents with high chorea than in those with low chorea.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Determinants of HRQoL: functional capacity and depressive mood
“Multiple regression analyses showed that functional capacity and depressive mood were significantly associated with HrQOL, in that greater impairments in HrQOL were associated with higher levels of depressive mood and lower functional capacity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Motor symptoms and cognitive function were not found to be as closely linked with HrQOL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric burden: suicidal ideation and sleep disturbance in the HDBOI study
“PwHD reported current (13%, n = 272) or previous (28%, n = 575) suicidal ideation, which was more common with advanced HD (ES, 11%; MS, 14%; AS, 15%; p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 482 questionnaire respondents, 91% (n = 437) reported difficulty sleeping, which was more common with AS HD (p < 0.05; [p = 0.000]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric burden: suicidal ideation measured with HDQLIFE Concern with Death and Dying items
“We examined 496 participants with premanifest or manifest HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our sample had a significantly higher occurrence of suicidal ideation (19.76%) and suicidal plans (2.1%) than the general population (p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. survey: individuals with HD and care partners compared with Parkinson's disease and the general population
“IHD had greater comorbid anxiety (IHD = 51.2%, IPD = 28.8%, GP = 2.0%), and HD-CP had greater comorbid anxiety (HD-CP = 52.5%, PD-CP = 28.6%, GP-CP = 19.6%) and depression (HD-CP = 65.0%, PD-CP = 29.9%, GP-CP = 19.6%), relative to other cohorts (p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respective of their GP cohorts, IHD exhibited lower HRQoL (EQ-5D: 0.66 ± 0.21 vs. 0.81 ± 0.17) and greater depression (PHQ-9: 11.59 ± 7.20 vs. 5.85 ± 6.71), whereas HD-CP exhibited greater depression only (PHQ-9: 6.84 ± 6.38 vs. 4.15 ± 5.58) (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Canada: HRQoL of individuals with HD and care partner strain
“A total of 62 adult individuals with HD (or their proxies) and 48 care partners met defined eligibility criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For individuals with HD, the greatest HRQoL burden (i.e., lowest score) was for the SF-36v1 Role -Physical scale (46.8 [42.9]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among care partners, 55.3% experienced high strain, as indicated by the CSI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden: prospective longitudinal study of patient and caregiver pairs
“105 caregiver/patient pairs were included in the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the two clusters of patients with advanced disease, cluster A was characterized by high levels of irritability and obsessive-compulsive behaviors, with high and increasing burden (N = 30; 29%), cluster B, the more apathetic group, with low and decreasing burden (N = 22; 21%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden: South Korea prospective cohort
“Sixty-five patients with HD and 45 caregivers were enrolled in this cohort study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A higher caregiver burden was associated with a more severe Shoulson-Fahn stage (p = 0.038) of the patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden: systematic review
“Twelve studies were included in the review involving 569 caregivers of patients with HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neuropsychiatric symptoms and the hereditary nature of the disease have been identified as important correlates of caregiver strain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient and caregiver experience: ICER stakeholder input
Multigenerational burden: qualitative study across six European countries
“Cognitive and psychiatric symptoms were particularly burdensome, driving declines in quality of life (QoL) and emotional well-being.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers reported extensive physical, financial, and psychological strain, with many assuming care responsibilities from a young age or eventually caring for multiple relatives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
U.S. commercial and Medicaid claims (2002 to 2009): direct medical costs by stage
“Among 1272 HD patients, the mean age was similar in commercial (752 patients) and Medicaid (520 patients) populations” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean total annualized cost per patient increased by stage (commercial: $4947 (SD = $6040)-$22,582 (SD = $39,028); Medicaid: $3257 (SD = $5670)-$37,495 (SD = $27,111).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The vast majority (73.8%) of Medicaid Late stage patients received nursing home care and the majority (54.6%) of Medicaid Late stage costs were associated with nursing home care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Key limitations include the classification of patients into a single stage, as well as a lack of visibility into full long-term care/nursing home-related costs for commercial patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. Medicare fee-for-service claims (2013 to 2017): costs versus matched beneficiaries and by stage
“We identified 3,688 matched pairs of beneficiaries with and without HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean [SD] annual total healthcare costs were higher for HD beneficiaries than beneficiaries without HD ($41,631 [57,393] vs. $17,222 [31,218], p < .001) and were primarily driven by outpatient pharmacy costs ($19,182 [45,469] vs. $4,318 [11,553], p < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the stratified analysis, total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $20,475 [$41,122] for early-stage vs. $29,733 [$44,977] for middle-stage vs. $56,657 [$64,185] for late-stage; p < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. Medicaid Analytic eXtract (2010 to 2014): costs versus matched beneficiaries and by stage
“A total of 1,785 beneficiaries without HD were matched to 595 beneficiaries with HD (139 early-, 78 middle-, and 378 late-stage).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) annual total costs were higher for beneficiaries with HD than beneficiaries without HD ($73,087 [$75,140] vs. $26,834 [$47,659], p <.001) and driven by inpatient costs ($45,190 [$48,185] vs. $13,808 [$39,596], p <.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $22,797 [$31,683] for early-stage HD vs. $55,294 [$129,290] for middle-stage HD vs. $95,251 [$60,197] for late-stage HD; p <.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. MarketScan commercial, Medicaid, and Medicare Supplemental claims (2009 to 2018): HRU and costs per patient per month by stage
“A total of 2,669 individuals with HD were identified. Of these, 1,432 (53.7%), 689 (25.8%), and 548 (20.5%) had early-, middle-, and late-stage HD at baseline, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean total all-cause healthcare cost PPPM for individuals with HD was $2,889, and it was significantly higher in middle-stage individuals, at $7,988, compared with early- and late-stage individuals, at $3,726 and $5,125, respectively; p <0.0001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our evaluations didn't include the indirect costs of HD, which may be substantial as HD typically affects people at their peak earning potential.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. MarketScan claims: costs versus propensity-matched controls without HD
“A total of 2,473 individuals with HD and 9,522 matched non-HD controls were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean total costs (2018 USD PPPM) for the HD cohort ($2,260 [SD = $4,682]) were twice the total costs in the non-HD cohort ($1,056 [SD = $3,078]) (P < 0.0001) and were highest across all disease stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. MarketScan claims: late-onset versus adult-onset HD
“In total, 763 individuals with LoHD and 1,073 individuals with AoHD were matched with 3,762 non-HD controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the 12 months post-index, mean total costs for the LoHD cohort ($29,055) were significantly higher than for non-HD controls (≥60 years old: $17,286; 21-59 years old: $12,688; p <.001) and similar to total costs in the AoHD cohort ($31,701; p =.47).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. MarketScan claims (2017 to 2021): HD-related costs by diagnosing provider type
“Three hundred and forty eligible patients had a mean age at diagnosis of 49 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HD-related mean costs totaled $2,489 ($1,179 inpatient and $1,310 outpatient).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients diagnosed by neurologists had significantly lower HD-related total non-medication costs vs. those diagnosed by PCPs (-$2,256; p < 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of cost-of-illness studies: annual costs by stage and cost type (2023 U.S. dollars)
Systematic review of cost-of-illness studies: synthesis
“Only five studies were included for extraction and synthesis including three from the USA, one from the United Kingdom (UK), and one from Peru.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outpatient costs were approximately 2.5 times greater than inpatient costs for early and middle stages of HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among all the costs associated with HD, annual caregiver cost emerges as the most significant costs in the economic burden of HD, ranging from a minimum of $6041 for early stage to a maximum of $133,200 for late-stage HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global systematic review: annual costs by region (2024 U.S. dollars)
“Out of the initial 608 de-duplicated articles, 19 full-text articles were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Annual costs in 2024 USD ranged significantly by region: Americas ($2542-$90,515), Europe ($40,000-$215,020), Asia ($1915-$7132), and Oceania ($3678-$8721).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study (France, Germany, Italy, Spain, United Kingdom, United States): direct, nondirect, and indirect costs
“HDBOI cost estimates were €12,663 (n = 2094) for direct medical costs, €2984 (n = 359) for nondirect medical costs, and €47,576 (n = 436) for indirect costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs are higher in patients who are at later stages of disease; for example, direct medical costs estimates were €9220 (n = 846), €11,885 (n = 701), and €18,985 (n = 547) for ES, MS, and AS, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs show large variations between patients and countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study: design, participants, and costing methods
“The HDBOI study is a noninterventional, retrospective, cross-sectional, international burden of illness study of people with diagnosed HD in France, Germany, Italy, Spain, the UK, and the USA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 2094 PwHD were enrolled in the HDBOI study, 40% of whom (n = 846) were classified as ES, 34% as MS (n = 701), and 26% as AS (n = 547; Table 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Information regarding HD-related health care resource use used to compute direct medical costs was available for all 2094 PwHD. Information on direct nonmedical costs was available for 359 PwHD and indirect costs for 436 PwHD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs are reported in 2020 euros for all outcomes” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To minimize underestimation of costs due to potentially reduced care interactions during the coronavirus disease 2019 (COVID-19) pandemic, health care resource use (used to compute direct medical costs) was extracted for a set time period before the pandemic (March 2019 through March 2020).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For actively employed PwHD and caregivers, productivity loss was quantified as the number of days missed from work due to HD in the past 3 months multiplied by the country average salary per day.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For those unable to work due to HD, an opportunity cost was assigned based on 1 year of average salary per country.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study: mean annual costs by disease stage (2020 euros)
HDBOI study: cost drivers and mean annual cost components by stage (2020 euros)
“Inpatient hospitalizations and residential care were the primary drivers of direct medical costs” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total costs (sum of direct medical, nonmedical, and indirect costs), available for a subsample of 307 PwHD (patients with a completed eCRF, PPIE-P, and PPIE-C), were driven primarily by indirect costs, which accounted for 84%, 80%, and 66% of ES, MS, and AS total costs, respectively (Appendix Table A2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study: mean annual costs by country (2020 euros)
“Direct nonmedical costs were highest in Italy (€3977) and the UK, and indirect costs were highest in the USA (€74,228 [$90,187]), the UK, and Italy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The HDBOI study reported direct medical costs of €27,743 in the USA and a substantial indirect cost burden of €74,228 from lost work productivity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDBOI study: stated limitations of the cost estimates
“Because recruitment was driven through clinician office visits, AS patients may have been underrepresented if they were admitted to long-term residential or nursing care homes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cost estimates for AS PwHD may have been underestimated due to the small sample of patients with advanced disease and subsequent subgroup analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For Germany, direct medical costs may have been underestimated, as only copayments were publicly available, which do not reflect the true cost of the service delivered.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom EHDN REGISTRY: annual societal costs by TFC stage (2013 pounds)
United Kingdom EHDN REGISTRY: cost drivers
“The mean annual cost per person with HD was £21 605. The largest proportion of this cost (65%) was due to informal care (£14 085).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This equates to £195 million per year in the UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Norway: six-month healthcare and societal costs
“Total six-month healthcare costs and total societal costs were € 18,538 and € 66,789 respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Main six-month cost components for the three disease phases were informal care costs (€ 30,605) accounting for approximately half the total societal costs, and costs due to production loss (€ 18,907) being slightly higher than the total healthcare costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term care in advanced HD: North American systematic literature review
Hospice and palliative care utilization in the United States
“Of the 164,032 patients admitted to these hospices, 101 (0.06%) had a primary diagnosis of HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had a median length of stay in hospice of 42 days, which was significantly longer than that of other hospice patients in the sample (17 days), P < 0.001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Predictors of health care utilization: Enroll-HD Northern America
“Visits from 1,631 participants in the Northern America region from the Enroll-HD study were included in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical factors, such as psychiatric symptoms, functional ability, and comorbidities, were associated with use of multiple types of health care services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Employment loss by disease stage: Enroll-HD
Employment and work productivity: HDBOI participants
Employment: chorea and cognitive decline
“Patients with chorea were less likely to be employed full-time (16.7% vs 25.7%; P<0.04) and more likely to be on long-term sick leave (17.4% vs 5.0%; P<0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For every year delay in cognitive symptom onset, there was a 0.806 year increase in age at leaving work (SE = 0.030, p < 0.001, adj-R2 = 0.628).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-three studies were identified and showed that while employment and working capacity in HD are negatively influenced by cognitive decline and motor impairments, apathy already plays a role in the prodromal stage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Canada (Alberta): direct healthcare costs under a universal public system
“The mean total all-cause direct healthcare costs were $23,211 [$38,599] per person-year, with hospitalizations accounting for 57.8% of all-cause costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs were higher among individuals with a long-term care stay, a proxy for disease severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other countries: Israel, China, Peru, Brazil, and Germany
“Total healthcare and medication costs per patient (US dollars) were significantly higher for PwHD than controls ($7,343 vs. $3,625; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average annual direct medical cost, direct non-medical cost, and indirect cost were 3,265.65, 805.82, and 801.97 Euros, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average annual cost of HD reached USD 8120 per patient in 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean cost of HD increased with the degree of patient dependency: from USD 6572 for Barthel 4 & 5 (slight dependency and total independency, respectively) to USD 23,251 for Barthel 1 (total dependency).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significant economic impacts were observed, with average annual direct medical costs of $4686.82 per HD patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-three out of 34 HD patients were unemployed or retired, and 16 relied on government benefits, reflecting broader socioeconomic implications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Physical therapy was the most often used medical aid in HD patients (46.4%). Nursing services and speech therapy were used by 27.9 and 22.7% of HD patients, respectively, whereas use of psychotherapy was rare (3.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Huntington's disease on families
Informal care and caregiver productivity costs: HDBOI study (2020 euros)
“Indirect costs for informal care were calculated as the total number of hours per week of informal care multiplied by the number of weeks per year. Total number of hours per year was multiplied by the country average salary per hour.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Caregiver state support accounted for 58%–75% of all direct nonmedical costs. Indirect costs were driven by lost productivity for PwHD (34%–42%) and costs of informal care requirements (40%–42%; Appendix Table A2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Cost component | Early stage, mean (SD) and n | Mid stage, mean (SD) and n | Advanced stage, mean (SD) and n |
|---|---|---|---|
| Informal care | “€27,760 (€37,790) n = 121”View highlighted excerpt for this quote | “€30,243 (€37,046) n = 120”View highlighted excerpt for this quote | “€37,758 (€45,515) n = 83”View highlighted excerpt for this quote |
| Lost productivity, caregiver | “€18,225 (€19,864) n = 33”View highlighted excerpt for this quote | “€12,988 (€15,621) n = 46”View highlighted excerpt for this quote | “€17,280 (€19,266) n = 49”View highlighted excerpt for this quote |
| State support, caregiver | “€5134 (€5834) n = 22”View highlighted excerpt for this quote | “€5897 (€5098) n = 36”View highlighted excerpt for this quote | “€4778 (€3359) n = 43”View highlighted excerpt for this quote |
Informal caregiver time and objective burden: France
“We included 80 ICs (mean [SD] age 57 [12.9] years, 60% women) in charge of 80 individuals with early to advanced stage HD” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean hours of informal care time was high: 7.3 (7.9) h/day (range 0-24); the mean professional home care was 2.8 (2.8) h/day (range 0.1-12.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The burden was partially related to the multiplex caregiving status (19%). Protective factors lowering the IC burden included the absence of financial hardship (57%), a strong social network (16%) and keeping active on the job market outside home (46%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver employment and work productivity: HDBOI caregivers
Caregivers of people with advanced HD in North America: systematic literature review
| Caregiver outcome | Quoted value |
|---|---|
| Mean time spent as primary carer (years) | “10.2 years” |
| Total hours of formal care per week | “43 hours” |
| Total hours of informal care per week | “41 hours” |
| Prevented career progression | “51%” |
| Prevented from working more hours | “70%” |
| Overall work productivity loss | “54%” |
Informal care as a share of societal cost: United Kingdom and Norway
“Informal care was the largest driver of costs across all stages of HD; thus there is a need to also consider the needs of carers when planning services for people with HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our results highlight the crucial role the informal caregivers play in the care provided to HD patients in all disease phases. Future research should focus on the estimation of productivity loss among informal caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket financing by families: Peru
“Direct non-healthcare costs represented 78.3% of total cost, indirect costs 14.4% and direct healthcare costs the remaining 7.3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct costs were primarily financed by patients and their families.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Juvenile-onset HD: costs to the NHS and to families (England and Wales, 2020 pounds)
“The overall mean JoHD cost to the NHS per year (2020) was £126,966 which varied according to disease severity, costing just under £11,000 in mild disease, £132,419 in moderate disease, and £221,797 in advanced JoHD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of indirect costs to families and carers was 64% for mild disease and 17% for advanced disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Family financial and care needs: ICER stakeholder input
At-risk family members: genetic discrimination in insurance
“Discrimination was reported by 93 respondents (39.9%). Reported experiences occurred most often in insurance (29.2%), family (15.5%), and social (12.4%) settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Family history of Huntington's disease, rather than the result of genetic testing, was the main reason given for experiences of genetic discrimination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across all three countries, a total of 46.2% of respondents report genetic discrimination or stigma based on either their family history of HD or genetic testing for the HD gene mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We report on the overall incidence of discrimination and stigma in the domains of insurance (25.9%), employment (6.5%), relationships (32.9%), and other transactions (4.6%) in the United States, Canada, and Australia combined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Cost of predictive genetic testing at HDSA Centers of Excellence in the United States
Predictive testing uptake among at-risk individuals
“9407 predictive tests were performed across 23 UK centres.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using a prevalence figure of 12.3 × 10−5, the cumulative uptake of predictive testing in the 50% at-risk UK population from 1994 to 2014 was estimated at 17.4% (95% CI: 16.9–18.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future therapies in HD will likely target presymptomatic individuals; therefore, identifying the at-risk population whose gene status is unknown is of significant public health value.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fear of health insurance loss and out-of-pocket payment for testing: North America
“After enrollment, 83 individuals [8.3%] pursued genetic testing. Their greatest concern was losing health insurance, and 41.6% of them [vs. 6.7% of those who did not pursue testing; P < 0.001] reported paying out of pocket for testing or other medical services to conceal their genetic risk from their insurer/employer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals who were tested, more United States residents [46.1%] than Canadian residents [0.0%; P = 0.02] paid out of pocket for health services or genetic testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insurance protections for genetic information in the United States
Access costs: travel, time away from work, and counseling
“Distance is a structural barrier, and relates to the time and travel required to access PT, the financial and other opportunity costs associated with taking time away from work and family to attend appointments and the stress of navigating urban centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Genetic counseling is necessary for presymptomatic or symptomatic HD genetic testing, but the lack of access to counseling because of geography or expense is a critical gap for many patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main advantage of tele-GC was reduction in travel time for both in-person GC first (n = 16) and tele-GC first (n = 11) participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Testing decisions when genetic services are fully funded: Israel
Demand for predictive testing after therapeutic trial news
Reproductive genetic testing: cost-effectiveness of preimplantation genetic testing
“Cost-effectiveness analysis in a theoretical cohort of 3,851 couples, where one individual is heterozygous for Huntington disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In vitro fertilization preimplantation genetic testing was associated with 77 more QALYs and a cost savings of $46,394,268.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most notably, in our theoretical cohort of couples, IVF preimplantation genetic testing resulted in 1,079 fewer Huntington disease-affected offspring.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
VMAT2 inhibitors
EHDN international guideline: first-line treatment of chorea
AAN evidence-based guideline on chorea (retired 2022): recommendation
“If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit. Occurrence of adverse events should be discussed and monitored, particularly depression/suicidality and parkinsonism with tetrabenazine and elevated liver enzymes with riluzole.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
German Neurological Society guideline: evidence for VMAT2 inhibitors and use of tetrabenazine
“The quality of data from RCTs is currently best for VMAT2 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of tetrabenazine (in combination or as monotherapy) is recommended if treatment with tiapride is either not tolerated or not efficacious.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MDS evidence-based review of treatments for Huntington's disease
“These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cochrane review of symptomatic treatments
“22 trials (1254 participants) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only tetrabenazine showed a clear efficacy for the control of chorea. The remaining pharmacological interventions revealed no clear effectiveness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HSG expert consensus: classes used for chorea in North American practice
“Despite the negative impact chorea can have on many aspects of day-to-day life, pharmacologic treatment remains underutilized in clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The two most common medication classes used to suppress chorea are vesicular monoamine transporter 2 (VMAT2) inhibitors and antipsychotics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tetrabenazine: FDA-approved indication and boxed warning
Tetrabenazine: label efficacy and functional outcomes in Study 1
Tetrabenazine: depression and sedation in the placebo-controlled trial
Tetrabenazine: TETRA-HD randomized trial
“The authors randomized 84 ambulatory patients with HD to receive TBZ (n = 54) or placebo (n = 30) for 12 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were five study withdrawals in the TBZ group and five serious adverse events (SAEs) in four subjects (drowning suicide, complicated fall, restlessness/suicidal ideation, and breast cancer) compared with one withdrawal and no SAEs in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deutetrabenazine: FDA boxed warning and label efficacy
Deutetrabenazine: First-HD randomized trial
“Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Valbenazine: FDA boxed warning and label efficacy
Valbenazine: parkinsonism in Huntington's disease
Valbenazine: KINECT-HD randomized trial
“Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo) and 127 were included in the safety-analysis set (64 assigned to valbenazine, 63 assigned to placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No suicidal behaviour or worsening of suicidal ideation was reported in participants treated with valbenazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HDSA physician's guide: indications for pharmacologic treatment of chorea
Antipsychotics
EHDN international guideline: second-generation neuroleptics for chorea and psychiatric symptoms
German Neurological Society guideline: tiapride as first-line antichoreic treatment
“Because of the favorable profile of side effects, in particular with regard to extrapyramidal (akathisia, Parkinsonism) and behavioral (depression) symptoms, the consensus in the Delphi group was that tiapride should be considered as first line treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparative studies (comparing head-to-head compounds for their ability to suppress hyperkinesias short- and long-term) are unavailable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AAN guideline (retired 2022): insufficient data for neuroleptics
HDSA physician's guide: off-label neuroleptics for chorea
International expert survey: first-choice antichoreic drug by region
“However, the experts did not agree on first choice of chorea drug, with the majority of experts in Europe favoring an antipsychotic drug (APD), and a near equal split in first choice between an APD and tetrabenazine (TBZ) among experts from North America and Australia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antidepressants and other psychiatric pharmacotherapy
EHDN international guideline: depression, irritability, and anxiety
HDSA physician's guide: pharmacotherapy for depression
German Neurological Society guideline: psychiatric symptoms
Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis, and sleep disorders
“An international committee of 11 multidisciplinary experts proposed a series of statements regarding the description and management of each symptom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High-level agreement (≥85% experts strongly agreed or agreed) was reached for 107 of the 110 statements that have been incorporated into the expert-based clinical recommendations presented herein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of pharmacological treatment of neuropsychiatric symptoms
“Fifteen articles qualified for critical evaluation: 10 randomized controlled trials (RCTs) (five placebo-controlled and five cross-over) and five open label studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As a result, convincing evidence that could guide clinical practice is lacking.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rehabilitation and nutritional therapies
EHDN international guideline: physiotherapy and exercise
EHDN international guideline: speech and language therapy and nutrition
EHDN international guideline: cognitive symptoms
Physical therapy clinical recommendations
“We recommend the following specific physical therapy interventions for people with HD: aerobic exercise (grade A evidence), alone or in combination with resistance training to improve fitness and motor function, and supervised gait training (grade A evidence) to improve spatiotemporal features of gait.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
German Neurological Society guideline: speech and occupational therapy
“Therefore, involving speech therapists in the multidisciplinary care of HD patients is essential.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Symptom-based psychosocial interventions such as psychological procedures, occupational therapy, and physical activity are recommended to stabilize and maintain everyday functions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
Current therapies are symptomatic. No approved therapy delays onset or slows progression, and a Cochrane review of 8 trials involving 1,366 participants found no pharmacological intervention effective as a disease-modifying therapy. Only chorea has FDA-approved treatments. All three approved VMAT2 inhibitors carry boxed warnings for depression and suicidality: in the tetrabenazine placebo-controlled trial, depression or worsening depression was reported in 10 of 54 participants (19%) versus 0 of 30 receiving placebo, and tetrabenazine is contraindicated in untreated or inadequately treated depression, a common feature of the disease. Chorea benefit does not persist after discontinuation; scores returned to baseline 1 to 2 weeks after stopping tetrabenazine, deutetrabenazine, and valbenazine. The tetrabenazine label reports no difference from placebo on functional capacity and cognition, with a nominally significant decrement on one functional measure, and valbenazine labeling states that drug-induced parkinsonism can cause more functional disability than untreated chorea in some patients. Antipsychotics, antidepressants, and rehabilitation are used largely on the basis of expert consensus: the MDS review found no eligible evidence for treatments of depression, psychosis, irritability, apathy, or suicidality, or for physiotherapy, occupational therapy, exercise, or dietary interventions, and a systematic review identified 15 eligible studies of neuropsychiatric treatment. Guidelines differ on the first-line antichoreic agent (tetrabenazine in EHDN guidance; tiapride in DGN guidance), and no blinded head-to-head comparison is available. Investigational huntingtin-lowering therapies have not yet produced an approved product: tominersen phase 3 dosing was discontinued in 2021, and in an ad hoc week 69 analysis of the 791-participant GENERATION HD1 trial the cUHDRS change with the every-8-week regimen was significantly worse than with placebo (-0.54 points; adjusted P=0.001), with more adverse events than in the placebo and every-16-week groups; pridopidine missed its phase 3 primary endpoint and received a negative CHMP opinion in 2025, and after a January 2026 Type A meeting the FDA stated that AMT-130 phase I/II data compared with an external control were not sufficient as primary evidence of effectiveness before later agreeing to accept a BLA for accelerated approval.
Absence of disease-modifying therapy
Tetrabenazine: contraindication in depression
Limited trial evidence in a rare disease
Investigational HTT lowering: tominersen phase 3 treatment stopped, with worse cUHDRS change at the every-8-week regimen
“On the basis of an overall benefit–risk assessment by an independent data monitoring committee, treatment was stopped in March 2021” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the every-8-week tominersen group, the mean change from baseline in the score on the cUHDRS at week 69 was significantly worse than that in the placebo group (−0.54 points, adjusted P=0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The role of antisense oligonucleotide–related toxic effects (possibly inflammatory in nature), as compared with total HTT lowering, on the outcomes observed in GENERATION HD1 cannot be distinguished, given the close relationship between drug exposure and HTT lowering.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
SKY-0515 is investigational and has no established place in therapy. Its studied use is as a once-daily oral therapy intended to slow disease progression, added to symptomatic care, in adults with symptomatic early disease: the phase 1/2 trial enrolled HD-ISS stage 1, stage 2, or mild stage 3 participants, and the FALCON-HD phase 2/3 trials enroll participants with stage 2 and early stage 3 disease, with registry eligibility thresholds of TFC 10 or higher and TMS 6 or higher. FALCON-HD 004-ANZ enrolled 144 participants in Australia and New Zealand; planned enrollment in FALCON-HD 004-WW was stated as up to an additional 400 participants in a July 2026 announcement and as approximately 600 participants in the September 2026 fifteen-month announcement. In HD-ISS terms, stage 2 denotes a measurable clinical phenotype and stage 3 denotes functional decline; clinical motor diagnosis corresponds to the latter part of stage 2. If approved, SKY-0515 would be used alongside, not in place of, symptomatic VMAT2 inhibitors, antipsychotics, antidepressants, and rehabilitation. Because administration is oral, SKY-0515 would not require the intrathecal injections used for tominersen or the MRI-guided neurosurgical procedure used for AMT-130. Specialist HD care in the United States is concentrated in the HDSA Centers of Excellence network (60 centers and 9 partner sites covering 37 states plus the District of Columbia), and the multidisciplinary care described in guidelines would continue regardless of disease-modifying treatment.
Studied population: FALCON-HD phase 2/3 trials
Anticipated administration: once-daily oral dosing
Target stages: HD Integrated Staging System
“If there are signs of neurodegeneration, evidenced by atrophy of the caudate or putamen, individuals are assigned to stage 1. If disease signs are measurable by the TMS or Symbol Digit Modalities Test (SDMT), they are classified as stage 2. Finally, if there is an impact on daily functioning as assessed by the Total Functional Capacity (TFC) or the Independence Scale, individuals are assigned to stage 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These initial stages, which have only recently become a focus of study, are particularly promising as they may reveal the most effective targets for disease-modifying therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HD-ISS as a framework for earlier intervention
Comparator care setting: neurosurgical administration of AMT-130
Specialist care setting: HDSA Centers of Excellence
Heterogeneity of treatment effect
Baseline severity imbalance between extension dose groups
Subgroup efficacy results by stage, CAG repeat length, or dose
No evidence found.
Care management intervention strategies
EHDN multidisciplinary position paper: managed care network and case manager
“The multidisciplinary team should be composed of different professionals who work closely together and interact within the group. It is also important to establish an individualised care and treatment plan for every single case of a patient and family. A case manager or coordinator may facilitate the work of the multidisciplinary team.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This position paper reveals that there are key essential professional groups involved in the MDT who do not have an HD guideline available, like psychologists, social workers, nurses, case managers and general practitioners.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HDSA physician's guide: team care and Centers of Excellence
HDSA Centers of Excellence: team composition
Advance care planning: EHDN guideline
Advance care planning and psychosocial support: German Neurological Society guideline
“Early in the disease process, it is recommended to document living wills and care directives” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, there should be support from a social worker to navigate the complex bureaucracy to apply for and obtain financial assistance and support for care needs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Advance care planning: multicenter HDQLIFE study
Palliative care in advanced disease: scoping review
“Our search resulted in 333 articles, 38 of which were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most literature was underpinned by a low level of evidence, except for the topics on social care (Level III-V), advance care planning (Level II-V) and end-of-life needs assessments (Level II-III).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
For symptomatic therapy, the expected outcome is symptom control; guidelines state that treatment goals are to reduce symptom burden, maximize function, and optimize quality of life. For a disease-modifying therapy such as SKY-0515, the expected outcome is slower clinical progression, measured in current trials by change in the cUHDRS, a composite of TFC, TMS, SDMT, and Stroop Word Reading, and by its TFC component. An anchor-based analysis of registry data proposed a cUHDRS decline of 1.2 points as a clinically meaningful within-patient change. The sponsor of AMT-130 reported in 2025 that the FDA considered the cUHDRS an acceptable intermediate clinical endpoint for accelerated approval, and the phase 3 INVEST-HD trial of votoplam uses change in cUHDRS to month 36 as its primary endpoint. Other endpoints proposed for earlier-stage populations include time to HD-ISS stage 3 (functional decline); modeling of a 9-month or longer delay in that transition yielded feasible sample sizes. Decision modeling indicates that the health effects of a disease-modifying therapy depend on stage at treatment: a hypothetical therapy produced life-year and QALY gains in all modeled populations, and cost savings only in individuals treated before functional decline.
Composite clinical progression measure in early Huntington's disease
“Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinically meaningful change on the cUHDRS
Regulatory acceptance of cUHDRS as an intermediate clinical endpoint: sponsor-reported FDA feedback
Phase 3 disease-modifying trial endpoint: votoplam INVEST-HD
Time to functional decline as an endpoint
Cognitive endpoints and regulatory meaningfulness
Aims of disease-modifying treatment and modeled long-term outcomes
“Potential disease-modifying treatments (DMTs) such as gene therapy (GTx), antisense oligonucleotides (ASOs), and small molecule–based therapeutic approaches aim to provide long-term health benefits for people with HD by slowing down, arresting, or even reverting disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although hypothetical DMTs led to cost savings in the PFD population by delaying the cost burdens of functional decline, they increased costs in SF1 and SF2 populations by prolonging time spent in expensive progressive HD states.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expected outcomes of symptomatic chorea treatment
“By integrating pharmacologic therapy with multidisciplinary care and holistic, goal-oriented communication about the impact of chorea, clinicians can meaningfully improve safety, independence, and quality of life for individuals and families affected by HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote